June Schema: S T R A I T I F Y. Age 1. <50 2. >50

Size: px
Start display at page:

Download "June Schema: S T R A I T I F Y. Age 1. <50 2. >50"

Transcription

1 June RTOG Protocol No: 9813 Protocol Status: ECOG Protocol No: R9813 Opened: June 16, 2000 NCCTG Protocol No: R9813 SWOG Protocol No: R9813 Title: A Phase / Randomized Study of Radiation Therapy and Temozolomide versus Radiation Therapy and BCNU for Anaplastic Astrocytoma (ND #60,265) Patient Population: - Histologically confirmed anaplastic astrocytoma or mixed oligodendroglial/astrocytic tumors if the oligodroglial component is < 25%. - No prior irradiation to the head, neck, or chemotherapy for any reason - Karnofsky performance status > 60 - Hgb > 10, absolute neutrophils > 1500, platelets > 150,000; liver function tests (AST/SGOT, alkaline phosphatase, total bilirubin < 2 x upper limit of normal); serum creatinine < 1.5 x normal. - Therapy must begin within 5 weeks after tissue diagnosis - No spinal cord tumors or spinal cord metastases - No prior invasive malignancy unless disease free > 5 years - No active infectious process - DLCO > 70% - Signed study-specific consent form prior to randomization Objective: 1. To compare overall survival. 2. To compare time to tumor progression. 3. To compare the relative toxicities of the two drug regimens. 4. To correlate molecular analyses with #1 and #2. Schema: S T R A T F Y Age 1. <50 2. >50 KPS Surgery 1. Biopsy only 2. Resection R A N D O M Z E Arm 1: Radiation Therapy: 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus Temozolomide 200 mg/m 2 daily on days 1-5 of the first week of radiotherapy. Repeat Temozolomide every 28 days for a total of 12 cycles. Arm 2: Radiation Therapy: 59.4 Gy (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus BCNU (80 mg/m 2 ) on days 1, 2, and 3 of the first week of radiotherapy and on days 56, 57, and 58 then every eight weeks for four cycles for a total of six cycles (maximum BCNU dose 1440 mg/m 2 ) Pilot #1, Arm 4: Pilot #2, Arm 5: Radiation Therapy: 59.4 (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus BCNU 200 mg/m 2 on day 1 of radiotherapy and Temozolomide 150 mg/m 2 on days 1-5 of the first week of radiotherapy. Repeat every six weeks for a total of six cycles (maximum BCNU dose 1200 mg/m 2 ). (closed 3/15/01) Radiation Therapy: 59.4 (1.8 Gy x 33 fractions, 5 days a week x 6 weeks) plus BCNU 150 mg/m 2 on day 5 of radiotherapy and Temozolomide 150 mg/m 2 on days 1-5 of the first week of radiotherapy. Repeat every eight weeks for a total of six cycles. BCNU will be given on day 5 of Temozolomide in these cycles (maximum BCNU dose 900 mg/m 2 ). (closed 1/25/02)

2 June Study Chairs: Statisticians: Research Associate: Dosimetrist: Protocol Associate: Susan M. Chang, M.D. Gregory J. Cairncross, M.D. Mark. R. Gilbert, M.D. Jean-Paul Bahary, M.D. Carol A. Dolinskas, M.D. Ken Aldape, M.D. Peter Bushunow, M.D. (ECOG) Paul Brown, M.D. (NCCTG) Jan Buckner, M.D. (NCCTG) Geoffrey R. Barger, M.D. (SWOG) Charles Scott, Ph.D. Rebecca Paulus, B.S. Barbara Kaiser, R.N., C.C.R.P. Elizabeth Martin, B.S., R.T.T. Linda Walters-Page, M.A.. Summary: This study had two pilot arms in order to assess the toxicity and feasibility of combining BCNU and Temozolomide. Fifteen patients were enrolled on Pilot #1, which closed March 15, Fourteen patients were enrolled on Pilot #2, which closed January 25, The phase component was activated January The institutional accrual for the phase component is listed in Table 2.3. Pretreatment characteristics appear in Table 3.1. There were two grade 3 neurologic toxicities on Pilot #1 and none on Pilot #2. There were 5 grade 3-4 infections on Pilot #1 and one on Pilot #2 (Table 4.1). t has been determined that the combination of RT + Temozolomide + BCNU is not feasible, thus that arm has been discontinued.. Administrative nformation: Table 2.1 Patient Accrual Total Patients Entered on the Pilot Arms 29 Estimated number of patients needed to be randomized 454 Total randomized as of 5/1/03 17

3 June Table 2.2 Patient Accrual by Participating nstitution RTOG (N=42) Thomas Jefferson University Hospital 6 Baptist Hospital of Miami 2 Dixie Medical Cancer Center 2 Foundation for Cancer Res. and Edu. 3 ngalls Memorial Hospital 2 Kansas City CCOP 2 Natalie Warren Bryant CC at St. Francis Hosp. 2 Notre Dame Hospital/University of Montreal 2 SE Cancer Control Consortium, nc. CCOP 2 University of Utah Health Science Center 2 University of Wisconsin Hospital 2 Cancer Research for the Ozarks 1 Central llinois CCOP 1 Cleveland Clinic Foundation 1 Dartmouth Hitchcock Medical Center 1 Dayton CCOP 1 Joe Arrington Cancer Res. & Treatment Ctr. 1 LDS Hospital 1 Lutheran General Hospital 1 Metro-MN CCOP 1 The Wendt Regional CC of the Finley Hosp. 1 Univ. of California Davis Medical Center 1 University of Rochester 1 University of Texas Medical Branch 1 Vanderbilt University Medical Center 1 Wake Forest Univ. Baptist Medical Center 1 SWOG (N=2) Oregon Health Sciences Center 1 University of Arkansas Medical Center 1 ECOG (N=1) Rochester General Hospital 1 NCCTG (N=1) Cedar Rapids 1 Table 2.3 Randomized Accrual by Participating nstitution RTOG (N=14) Baptist Hospital of Miami 2 Notre Dame Hospital/University of Montreal 2 Dartmouth Hitchcock Medical Center 1 Dixie Medical Cancer Center 1 Foundation for Cancer Res. and Edu. 1 Kansas City CCOP 1 LDS Hospital 1 Natalie Warren Bryant CC at St. Francis Hosp. 1 The Wendt Regional CC of the Finley Hosp. 1 Thomas Jefferson University Hospital 1 University of Rochester 1 University of Utah Health Science Center 1 SWOG (N=2) Oregon Health Sciences Center 1 University of Arkansas Medical Center 1 NCCTG (N=1) Cedar Rapids 1

4 June Table 2.4 Status of Cases Pilot #1 Pilot #2 RT + Temozolomide RT + BCNU Total Patients Entered Cancelled 0 1* 0 0 No On-study Form Eligible and Analyzable *CN Arm Reason 27 Pilot #2 Cancelled: Patient progressed prior to receiving treatment, refused any treatment. Pretreatment Characteristics: Table 3.1 Pretreatment Characteristics Pilot #1 (N=15) Pilot #2 (N=13) RT + Temozolomide (N=1) RT + BCNU (N=2) Age <50 8 (53%) 10 (77%) 0 1 (50%) 50 7 (47%) 3 (23%) 1(100%) 1 (50%) Gender Male 10 (67%) 7 (54%) 1(100%) 1 (50%) Female 5 (33%) 6 (46%) 0 1 (50%) Race White 13 (87%) 11 (85%) 1(100%) 2(100%) Hispanic 2 (13%) 1 ( 8%) 0 0 African American 0 1 ( 8%) 0 0 KPS 60 2 (13%) (53%) 3 (23%) 1(100%) 1 (50%) (33%) 10 (77%) 0 1 (50%) Surgery Biopsy 7 (47%) 5 (38%) 0 1 (50%) Partial Resection 5 (33%) 3 (23%) 1(100%) 1 (50%) Total Resection 3 (20%) 5 (38%) 0 0 Neurologic Function No Symptoms 4 (27%) 4 (31%) 0 0 Minor Symptoms 5 (33%) 7 (54%) 1(100%) 2(100%) Moderate Symptoms 6 (40%) 2 (15%) 0 0

5 June V. Toxicities: Table 4.1 Toxicities Pilot #1 N=15 Grade Pilot #2 N=13 Grade Auditory/Hearing Blood/Bone Marrow Thrombocytopenia Cardiovascular (General) * Constitutional Symptoms Dermatology/Skin 4 4 1* Gastrointestinal Hepatic nfection/febrile Neutropenia Lymphatics Metabolic/Laboratory Musculoskeletal Neurology 2 2 2* Ocular/Visual Pain Pulmonary 1 3 1* Renal/Genitourinary Maximum Toxicity per Patient Maximum Non-Hematologic Toxicity per Patient *CN Arm Toxicity Grade Most Recent Cycle of Chemotherapy Days from Start of RT 3 Pilot #1 Pulmonary: Dyspnea Pilot #1 Dermatology: Rash/desquamation Pilot #1 Neurology: Confusion Pilot #1 Cardiovascular (General): Thrombosis/embolism 4 2 Unknown 15 Pilot #1 Neurology: Vertigo

January Schema: S T R A T I F Y. Age 1. <50 2. >50

January Schema: S T R A T I F Y. Age 1. <50 2. >50 January 2004 9813-1 RTOG Protocol No: 9813 Protocol Status: ECOG Protocol No: R9813 Phase I: Opened June 16, 2000 NCCTG Protocol No: R9813 Closed January 25, 2002 SWOG Protocol No: R9813 Phase III: Opened

More information

June Patient Population:

June Patient Population: June 2003 9802-1 RTOG Protocol No: 9802 Protocol Status: ECOG Protocol No: R9802 Opened: October 31, 1998 NCCT Protocol No: R9802 Closed: June 27, 2002 SWOG Protocol No: R9802 Title: A Phase II Study of

More information

June Arm 1 = Observe R A N D O M I Z E

June Arm 1 = Observe R A N D O M I Z E June 2004 9802-1 RTOG Protocol No: 98-02 Protocol Status: ECOG Protocol No: R9802 Opened: October 31, 1998 NCCT Protocol No: R9802 Closed: June 27, 2002 SWOG Protocol No: R9802 Title: A Phase II Study

More information

January NCCTG Protocol No: N0628 Opened: November 27, 2007 CALGB Protocol No: ECOG Protocol No: R0617

January NCCTG Protocol No: N0628 Opened: November 27, 2007 CALGB Protocol No: ECOG Protocol No: R0617 January 2010 0617-1 RTOG Protocol No: 0617 Protocol Status: NCCTG Protocol No: N0628 Opened: November 27, 2007 CALGB Protocol No: 30609 ECOG Protocol No: R0617 Title: A Randomized Phase III Comparison

More information

Arm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks.

Arm A: Induction Gemcitabine 1000 mg/m 2 IV once a week for 6 weeks. ECOG-4201 (RTOG Endorsed) ECOG 4201 Pancreas (RTOG Endorsed)-1 Protocol Status: Opened: April 10, 2003 Closed: December 15, 2005 Title: A Randomized Phase III Study of Gemcitabine in Combination with Radiation

More information

June 2009 Respiratory Committee CALGB 30610

June 2009 Respiratory Committee CALGB 30610 30610 Phase III comparison of thoracic radiotherapy regimens in patients with limited small cell lung cancer also receiving cisplatin and etoposide Activated: March 15, 2008 Study Chairpersons: J. Bogart

More information

Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402

Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Chemotherapy plus Radiotherapy versus Radiotherapy Alone for Patients with Anaplastic Oligodendroglioma: Long Term Results of RTOG 9402 Gregory Cairncross, Meihua Wang, Edward Shaw, Berndt Scheithauer

More information

Objectives Primary Objective: Secondary Objectives For T4 a, b, c tumors:

Objectives Primary Objective: Secondary Objectives  For T4 a, b, c tumors: Z1031 A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen

More information

NCCTG Status Report for Study N April 2008

NCCTG Status Report for Study N April 2008 Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed lone as Second-line Therapy in Patients With dvanced Non-Small Cell Lung Cancer Purpose of - Primary Study: 1) To compare the progression-free

More information

NCCTG Status Report for Study N September 2007

NCCTG Status Report for Study N September 2007 Phase I/II Study of Concurrent Chemotherapy and Escalating Doses 3-D Conformal Radiotherapy (RT) Followed by Three Cycles of Chemotherapy for Unresectable Non-Small Cell Lung Cancer (NSCLC) Using a New

More information

6 cycles* January Opened: January 17, 2006

6 cycles* January Opened: January 17, 2006 January 2008 0525-1 RTOG Protocol No: 0525 Protocol Status: Opened: January 17, 2006 Title: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide in Patients with

More information

PROCARBAZINE, lomustine, and vincristine (PCV) is

PROCARBAZINE, lomustine, and vincristine (PCV) is RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine

More information

GOG PROTOCOL #209. David Miller, MD, Gini Fleming, MD, Richard Zaino, MD, and David Cella, PhD

GOG PROTOCOL #209. David Miller, MD, Gini Fleming, MD, Richard Zaino, MD, and David Cella, PhD GOG PROTOCOL #209 PROTOCOL Study Chairs Statistician Data Coordinator Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III and

More information

EORTC (RTOG 0834 Endorsed) Opened: July 22, 2009

EORTC (RTOG 0834 Endorsed) Opened: July 22, 2009 January 2011 0834-1 EORTC 26053 22054 (RTOG 0834 Endorsed) Protocol Status: Opened: July 22, 2009 Title: Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1P/19Q Deleted Anaplastic

More information

GOG PROTOCOL #209 GOG 209

GOG PROTOCOL #209 GOG 209 GOG PROTOCOL #209 PROTOCOL Study Chairs Statistician Data Coordinator Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients with Stage III and

More information

NCCTG Status Report for Study N May 2010

NCCTG Status Report for Study N May 2010 Phase I/II Study of Vorinostat (Suberoylanilide Hydroxamic cid SH), Temozolomide, and Radiation Therapy in Patients with Newly Diagnosed Glioblastoma Purpose of - Phase I Study: 1) To determine the maximum

More information

Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma

Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma Feasibility Trial of Optune for Children with Recurrent or Progressive Supratentorial High-Grade Glioma and Ependymoma ABSTRACT Recurrent or progressive pediatric CNS tumors generally have a poor prognosis

More information

S0106 Phase III. Coordinating Group: SWOG

S0106 Phase III. Coordinating Group: SWOG S0106 Phase III Coordinating Group: SWOG A Phase III Study of the Addition of Gemtuzumab Ozogamicin (Mylotarg ) Induction Therapy Versus Standard Induction with Daunomycin and Cytosine Arabinoside Followed

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema This is a phase I/II study to determine: 1) the maximum tolerated dose (MTD) or recommended phase II dose of ABT-888 in combination with radiation therapy, and 2) the efficacy

More information

EASTERN COOPERATIVE ONCOLOGY GROUP

EASTERN COOPERATIVE ONCOLOGY GROUP EASTERN COOPERATIVE ONCOLOGY GROUP E5204 INTERGROUP RANDOMIZED PHASE III STUDY OF POSTOPERATIVE OXALIPLATIN, 5-FLUOROURACIL AND LEUCOVORIN VS OXALIPLATIN, 5-FLUOROURACIL, LEUCOV- ORIN AND BEVACIZUMAB FOR

More information

Abstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Abstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema A Phase 1 and Phase II Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary

More information

HSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2

HSV1716 Dose levels and Cohort size Dose level No of Patients HSV1716 Dosage 1* 3 to 6 1 ml of 1 x 10 5 infectious units HSV1716 per ml 2 Abstract and Schema: Description and Rationale: Pediatric high grade gliomas have a progressive initial course and high risk of relapse/ progression; making the 5-year overall survival rate 15-35% with

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema Phase II study of Bevacizumab plus Irinotecan (Camptosar ) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas,

More information

Abstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Abstract and Schema. Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Abstract and Schema Phase 1 and Pharmacokinetic Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma Description and Rationale: Low grade gliomas are among the most common primary CNS

More information

Collection of Recorded Radiotherapy Seminars

Collection of Recorded Radiotherapy Seminars IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation

More information

CNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician

CNAJ12TZRT. Protocol Code. Neuro-Oncology. Tumour Group. Dr. Brian Thiessen. Contact Physician BC Cancer Protocol Summary for Concomitant (Dual Modality) and 12 Cycles of Adjuvant Temozolomide for Newly Diagnosed Astrocytomas and Oligodendrogliomas with Radiation Protocol Code Tumour Group Contact

More information

June 2009 Breast Committee CALGB 40502

June 2009 Breast Committee CALGB 40502 CALGB 40502/CTSU 40502 A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound nabpaclitaxel or ixabepilone combined with bevacizumab as first-line therapy for locally

More information

Objectives Primary Objectives:

Objectives Primary Objectives: Z1031 A randomized phase III trial comparing 16 to 18 weeks of neoadjuvant exemestane (25mg daily), letrozole (2.5mg), or anastrozole (1mg) in postmenopausal women with clinical stage II and III estrogen

More information

Cancer Research Group Version Date: November 5, 2015 NCI Update Date: January 15, Schema. L O Step 1 1,2

Cancer Research Group Version Date: November 5, 2015 NCI Update Date: January 15, Schema. L O Step 1 1,2 Cancer esearch roup ev. 6/14, 2/15, 1/16 Step 2 Schema 5 Arm A: (7 weeks) Step 1 1,2 N Accrual: 515 S Arm S ransoral esection dissections S A N D M Z 4 ntermediate isk 7 Stratify: = 10 pk-yr vs. > 10 pk-yr

More information

Plattenepithelkarzinom des Ösophagus, 1 st -line

Plattenepithelkarzinom des Ösophagus, 1 st -line Plattenepithelkarzinom des Ösophagus, 1 st -line AIO-STO-0309 An open-label, randomized phase III trial of cisplatin and 5-fluorouracil with or without panitumumab for patients with nonresectable, advanced

More information

BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy

BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent Adjuvant Temozolomide Radiation Therapy Protocol Code Tumour Group Contact Physician CNELTZRT Neuro-Oncology

More information

Subject ID: I N D # # U A * Consent Date: Day Month Year

Subject ID: I N D # # U A * Consent Date: Day Month Year IND Study # Eligibility Checklist Pg 1 of 15 Instructions: Check the appropriate box for each Inclusion and Exclusion Criterion below. Each criterion must be marked and all protocol criteria have to be

More information

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib)

Sponsor / Company: Sanofi Drug substance(s): SAR (iniparib) These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):

More information

June Opened: January 17, 2006 Closed: June 13, 2008

June Opened: January 17, 2006 Closed: June 13, 2008 June 2009 0525-1 RTOG Protocol No: 0525 Protocol Status: Opened: January 17, 2006 Closed: June 13, 2008 Title: Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-Intensive Temozolomide

More information

SUMMARY OF CHANGES Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010]

SUMMARY OF CHANGES Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010] Amendment 6, Version Date: March 29, 2010 [Broadcast: April 8, 2010] RTOG 0233, "A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema A Phase I Trial of p28 (NSC745104), a Non-HDM2 mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive CNS tumors Description and

More information

(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)

(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA) Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded

More information

Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas

Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas RTOG 0539 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Volume 4, Issue 2 September 2012 I N T HIS I SSUE Thoughts From the Chair

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, Celgene Corporation 86 Morris Avenue Summit, New Jersey 07901 Tel 908-673-9000 Fax 908-673-9001 October 2012 NEW Indication Announcement for ABRAXANE for Injectable Suspension (paclitaxel protein-bound

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating

More information

Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer

Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Chemoradiation (CRT) Safety Analysis of ACOSOG Z6041: A Phase II Trial of Neoadjuvant CRT followed by Local Excision in ut2 Rectal Cancer Emily Chan, Qian Shi, Julio Garcia-Aguilar, Peter Cataldo, Jorge

More information

NRG ONCOLOGY NRG-CC003

NRG ONCOLOGY NRG-CC003 NRG ONCOLOGY NRG-CC003 A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer SCHEMA Histologic proof or unequivocal cytologic

More information

Neuro-Oncology Program

Neuro-Oncology Program Neuro-Oncology Program The goals of the Neuro-oncology Committee are: 1) to improve duration and quality of life of brain tumor patients; 2) to assess disease and treatment-related effects on neurocognitive

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced

More information

The 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract

The 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against

More information

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare

21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology

More information

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer

Irinotecan. Class:Camptothecin. Indications : _Cervical cancer. _CNS tumor. _Esophageal cancer. _Ewing s sarcoma. _Gastric cancer Irinotecan Class:Camptothecin Indications : _Cervical cancer _CNS tumor _Esophageal cancer _Ewing s sarcoma _Gastric cancer _Nonsmall cell lung cancer _Pancreatic cancer _Small cell lung cancer _Colorectal

More information

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause.

Primary Endpoint The primary endpoint is overall survival, measured as the time in weeks from randomization to date of death due to any cause. CASE STUDY Randomized, Double-Blind, Phase III Trial of NES-822 plus AMO-1002 vs. AMO-1002 alone as first-line therapy in patients with advanced pancreatic cancer This is a multicenter, randomized Phase

More information

PRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study

PRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor

More information

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support

Adjuvant Therapy in Locally Advanced Head and Neck Cancer. Ezra EW Cohen University of Chicago. Financial Support Adjuvant Therapy in Locally Advanced Head and Neck Cancer Ezra EW Cohen University of Chicago Financial Support This program is made possible by an educational grant from Eli Lilly Oncology, who had no

More information

GOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist:

GOOVIPPC. Protocol Code: Gynecology. Tumour Group: Paul Hoskins. Contact Physician: James Conklin. Contact Pharmacist: BCCA Protocol Summary for Primary Treatment of Stage III less than or equal to 1 cm Visible Residual Invasive Epithelial Ovarian Cancer or Stage I Grade 3 or Stage II Grade 3 Papillary Serous Ovarian Cancer

More information

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD

ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD ACOSOG (NCCTG, CALGB) Alliance Thoracic Committee Kemp H. Kernstine, MD PhD 7-12-12 ACOSOG Thoracic Committee Chair: Bryan Meyers, M.D., MPH Vice Chairs: Malcolm Brock, MD Tom DiPetrillo, M.D. Ramaswamy

More information

Synopsis. Study Phase and Title: Study Objectives: Overall Study Design

Synopsis. Study Phase and Title: Study Objectives: Overall Study Design Synopsis Study Phase and Title: Study Objectives: Overall Study Design Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib

More information

Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer*

Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer* Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer* Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group William

More information

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar

Welcome to. American College of Surgeons. Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar American College of Surgeons Clinical Research Program Kelly K. Hunt, M.D. Program Director Welcome to American College of Surgeons Clinical Research Program (ACS-CRP) Breast Surgical Trial Webinar Moderator:

More information

January Opened: April 15, 2009

January Opened: April 15, 2009 January 2011 0825-1 RTOG Protocol No: 0825 Protocol Status: Opened: April 15, 2009 Title: Phase III Double-Blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide

More information

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.

Docetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled

More information

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: Date: 18 February 2008

ClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: Date: 18 February 2008 These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov

More information

SUMMARY OF CHANGES Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10

SUMMARY OF CHANGES Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10 Amendment 5, Version Date: March 24, 2010 Broadcast: 4/6/10 RTOG 0239, "A Phase II Study Of Accelerated High Dose Thoracic Irradiation With Concurrent Chemotherapy For Patients With Limited Small Cell

More information

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract

Trabectedin in ASTS. Le Cesne A, et al. J Clin Oncol. 2018;36(suppl): Abstract Results of a Prospective Randomized Phase III T-SAR Trial Comparing Trabectedin vs Best Supportive Care (BSC) in Patients With Pretreated Advanced Soft Tissue Sarcoma (ASTS) Abstract 11508 Le Cesne A,

More information

BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy

BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy BCCA Protocol Summary for Curative Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GICART Gastrointestinal

More information

Antiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA)

Antiemetic protocol for low-moderately emetogenic chemotherapy (see SCNAUSEA) BC Cancer Protocol Summary for First Line Treatment of Locally Advanced Metastatic Pancreatic Cancer with Gemcitabine Protocol Code Tumour Group Contact Physician GIPGEMABR Gastrointestinal GI Systemic

More information

Phase I Trial of Siplizumab in CD-2 Positive Lymphoproliferative Disease

Phase I Trial of Siplizumab in CD-2 Positive Lymphoproliferative Disease Phase I Trial of Siplizumab in CD-2 Positive Lymphoproliferative Disease J E Janik 1, D O Mahony 1, JC Morris 1, L Moses 1, D O Hagan 1, W Gao 1, M A Stetler-Stevenson 1, M Taylor 2, L Hammershaimb 2 T

More information

Special pediatric considerations are noted when applicable, otherwise adult provisions apply.

Special pediatric considerations are noted when applicable, otherwise adult provisions apply. DRUG NAME: Lomustine SYNONYM(S): CCNU 1 COMMON TRADE NAME(S): CeeNU CLASSIFICATION: alkylating agent Special pediatric considerations are noted when applicable, otherwise adult provisions apply. MECHANISM

More information

Contemporary Management of Glioblastoma

Contemporary Management of Glioblastoma Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I

More information

Hypofractionated radiation therapy for glioblastoma

Hypofractionated radiation therapy for glioblastoma Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health

More information

NCCTG Status Report for Study N May 2010

NCCTG Status Report for Study N May 2010 MARVEL: Marker Validation of Erlotinib in Lung Cancer - A Phase III Biomarker Validation Study of Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Randomized to Pemetrexed

More information

Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer (NCT )

Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer (NCT ) Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for childhood brain cancer (NCT02502708) Theodore S. Johnson, M.D., Ph.D. Pediatric Immunotherapy Program Medical College of Georgia (MCG) Georgia

More information

Management of Brain Metastases Sanjiv S. Agarwala, MD

Management of Brain Metastases Sanjiv S. Agarwala, MD Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):

More information

Dr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah

Dr. Sause: Clinical, Research, and Administration. Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Dr. Sause: Clinical, Research, and Administration Vilija N. Avizonis, MD Radiation Oncologist; Intermountain Medical Center; Murray, Utah Objectives: Identify Dr. Sause's educational achievements Discuss

More information

PREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin

PREHYDRATION: 1000 ml NS with potassium chloride 20 meq and magnesium sulphate 2 g IV over 1 hour prior to CISplatin BC Cancer Protocol Summary for Treatment of Newly Diagnosed Nasal, Extranodal Natural Killer (NK) or T-cell lymphoma, using Concurrent Radiation and weekly CISplatin followed by Etoposide, Ifosfamide,

More information

Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting (NCT )

Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting (NCT ) Radio-chemo-immunotherapy using the IDO-inhibitor indoximod for children with progressive brain tumors in the phase 1 setting (NCT02502708) Theodore S. Johnson, M.D., Ph.D. Pediatric Immunotherapy Program

More information

The Clinical Research E-News

The Clinical Research E-News Volume 3: ISSUE 11: June 15, 2011 The Clinical Research E-News Reminder: CRA Quarterly Meeting, Philadelphia, PA: 10-11am on Wednesday June 22nd- Virtual Meeting: dial information attached in a separate

More information

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients

Panitumumab After Resection of Liver Metastases From Colorectal Cancer in KRAS Wild-type Patients 1 von 5 23.11.2011 10:52 Home Search Study Topics Glossary Full Text View Tabular View No Study Results Posted Related Studies Panitumumab After Resection of Liver Metastases From Colorectal Cancer in

More information

ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER

ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER ORIGINAL ARTICLE CHEMOTHERAPY ALONE FOR ORGAN PRESERVATION IN ADVANCED LARYNGEAL CANCER Vasu Divi, MD, 1 * Francis P. Worden, MD, 1,2 * Mark E. Prince, MD, 1 Avraham Eisbruch, MD, 3 Julia S. Lee, MD, 4

More information

NSABP PROTOCOL B-34. Date Opened to Randomization: December 1, 2000 Date Closed to Randomization: March 31, 2004 Number of Patients Randomized: 3,323

NSABP PROTOCOL B-34. Date Opened to Randomization: December 1, 2000 Date Closed to Randomization: March 31, 2004 Number of Patients Randomized: 3,323 NSABP PROTOCOL B-34 A Clinical Trial Comparing Adjuvant Clodronate Therapy versus Placebo in Early-Stage Breast Cancer Patients Receiving Systemic Chemotherapy and/or Tamoxifen or No Therapy Date Opened

More information

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib

BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib BC Cancer Protocol Summary for Therapy of Acute Myeloid Leukemia Using azacitidine and SORAfenib Protocol Code Tumour Group Contact Physician ULKAMLAS Leukemia/BMT Dr. Donna Hogge ELIGIBILITY: Acute myeloid

More information

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL):

Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages I-II Hodgkin s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial H. Eghbali, P.

More information

Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus

Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre

More information

COG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)

COG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) Page 1 of 6 COG-ACNS1123: Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT) FAST FACTS Eligibility Reviewed and Verified By

More information

Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS

Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221. Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS Clinical Trials in Transoral Endoscopic Head &Neck Surgery ECOG3311 and RTOG1221 Chris Holsinger, MD, FACS Bob Ferris, MD, PhD, FACS 1 Disclosure I have no conflicts of interest to disclose 2 Robotic H&N

More information

Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas

Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas Neurosurg Focus 4 (4):Article 3, 1998 Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas Albert Moghrabi, M.D., Henry S. Friedman, M.D., David M. Ashley, M.B.B.S., Ph.D., Krystal S.

More information

The Clinical Research E-News

The Clinical Research E-News The Clinical Research E-News Volume 7: ISSUE 1: January 16, 2015 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials

More information

NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA

NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA NON-SURGICAL STRATEGY FOR ADULT EPENDYMOMA Roberta Rudà Department of Neuro-Oncology University and City of Health and Science Hospital of Turin, Italy EORTC EANO ESMO Conference 2015 Istanbul, March 27-28

More information

Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience

Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,

More information

BRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician

BRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician

More information

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014

Systemic Treatment. Third International Neuro-Oncology Course. 23 May 2014 Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer

More information

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman

RTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG

More information

Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors

Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors Intra-arterial Targeted Delivery of Gemcitabine in Treatment of Patients with Loco-regional Pancreatic Tumors Alexander Rosemurgy, M.D., Sharona Ross, M.D., Paul Vitulli, M.D., Florida Hospital Tampa,

More information

FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated

FAST FACTS Eligibility Reviewed and Verified By MD/DO/RN/LPN/CRA Date MD/DO/RN/LPN/CRA Date Consent Version Dated Page 1 of 5 COG-AEWS1221: Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly

More information

Distal Pancreatectomy with Celiac Axis Resection: What Are the Added Risks?

Distal Pancreatectomy with Celiac Axis Resection: What Are the Added Risks? Distal Pancreatectomy with Celiac Axis Resection: What Are the Added Risks? Joal D. Beane, MD a, Michael G. House, MD a, Susan C. Pitt, MD c, E. Molly Kilbane a, Bruce L. Hall c, Abishek Parmar d, Taylor.

More information

Protocol Abstract and Schema

Protocol Abstract and Schema Protocol Abstract and Schema A Molecular Biology and Phase II Study of Imetelstat (GRN163L) in Children with Recurrent High-Grade Glioma, Ependymoma, Medulloblastoma/Primitive Neuroectodermal Tumor and

More information

Prior to 1993, the only data available in the medical

Prior to 1993, the only data available in the medical Neuro-Oncology Prospective clinical trials of intracranial low-grade glioma in adults and children Edward G. Shaw 1 and Jeffrey H. Wisoff Department of Radiation Oncology, Wake Forest University School

More information

Setting The setting was secondary care. The economic study was carried out in the UK.

Setting The setting was secondary care. The economic study was carried out in the UK. Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer Robinson P, von der Masse H, Bhalla S, Kielhorn A, Aristides M, Brown A, Tilden D

More information

PBTC-045: Abstract and Schema

PBTC-045: Abstract and Schema PBTC-045: A Safety and Preliminary Efficacy trial of MK-3475 (pembrolizumab; anti-pd-1) in Children with recurrent, progressive or refractory high-grade gliomas (HGG) and DIPGs Abstract and Schema This

More information

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION

More information

PREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with

PREMEDICATIONS: Antiemetic protocol for highly emetogenic chemotherapy. May not need any antiemetic with BCCA Protocol Summary for Palliative Therapy of Metastatic or Locally Advanced Gastric, Gastroesophageal Junction Adenocarcinoma, Esophageal Squamous Cell Carcinoma, or Anal Squamous Cell Carcinoma using

More information

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin)

SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) SAFETY CONSIDERATIONS WITH YONDELIS (trabectedin) Please see Important Safety Information on pages 14 and 15 and accompanying full Prescribing Information. YONDELIS (trabectedin) STUDY DESIGN INDICATION

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly

More information